FDA Expands Use of T-DXd in Early HER2+ Breast Cancer
The FDA has approved expanded use of trastuzumab deruxtecan (T-DXd) for patients with HER2-positive early breast cancer. This includes new indications for both neoadjuvant and adjuvant treatment settings. The approval is based on positive results from two phase 3 clinical trials, which showed significant benefits in patient outcomes.
- ▪T-DXd is now approved for neoadjuvant treatment in adults with HER2-positive stage II or III breast cancer.
- ▪In the adjuvant setting, the drug is approved for patients with residual invasive disease after neoadjuvant therapy.
- ▪The expanded indications are supported by results from the DESTINY-Breast11 and DESTINY-Breast05 trials.
2 outlets in our directory ran this story, first to last over 9 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
- ▪ AstraZeneca wins FDA approval for Enhertu in early breast cancer — Investing.com — News
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/fda-expands-use-t-dxd-early-her2-breast-cancer-2026a1000g1n?src=rss |
| Publication time | Mon, 18 May 2026 12:02:11 EDT |
| Retrieval time | 2026-05-18T16:04:56.662Z |
| Last seen | 2026-05-18T16:04:56.662Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 2QQSWdzs3jrg · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The FDA has approved two new indications for trastuzumab deruxtecan (T-DXd; Enhertu, AstraZeneca/Daiichi Sankyo), broadening the drug’s use for patients with HER2-positive early breast cancer and moving the therapy into potentially curative treatment settings. The expanded indications for the anti-HER2 antibody-drug conjugate cover both the neoadjuvant and adjuvant settings. In the neoadjuvant setting, T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP) is now approved for adults with HER2-positive (immunohistochemistry [IHC] 3+ or in situ hybridization [ISH]+) stage II or III breast cancer.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
